Table 7.

Trials’ subset and sensitivity analyses for prognostic analysis in the experimental arm for OS, PFS and ORR

	Main analysis	Trials’ subset analysis		Sensitivity analyses
		Type of anti-EGFR		Only phase III (without PEAK)	Only first line (without 20050181)
Parameter		Cetuximab	Panitumumab
OS
HR (95% CI)	2.03 (1.69–2.42)	2.11 (1.68–2.66)	1.90 (1.43–2.53)	1.99 (1.65–2.39)	2.03 (1.67–2.47)
P value	<0.001	<0.001	<0.001	<0.001	<0.001
P value for interactiona		0.57
P value for heterogeneity	0.46	0.25	0.44	0.54	0.46
PFS
HR (95% CI)	1.59 (1.34–1.88)	1.77 (1.43–2.20)	1.34 (1.02–1.75)	1.59 (1.33–1.89)	1.63 (1.35–1.96)
P value	<0.001	<0.001	0.03	<0.001	<0.001
P value for interactiona		0.11
P value for heterogeneity	0.58	0.73	0.73	0.58	0.65
ORR
OR (95% CI)	0.38 (0.28–0.50)	0.35 (0.25–0.50)	0.42 (0.27–0.66)	0.33 (0.24–0.44)	0.40 (0.30–0.53)
P value	<0.001	<0.001	<0.001	<0.001	<0.001
P value for interactiona		0.55
P value for heterogeneity	0.08	0.50	0.02	0.64	0.22

^aTest comparing the HRs between the two trial subsets (cetuximab, panitumumab).

HR, hazard ratio; OR, odds ratio; CI, confidence interval; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.